S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model

Shelly C. Lu, Komal Ramani, Xiaopeng Ou, Mark T Lin, Victor Yu, Kwangsuk Ko, Ryan Park, Teodoro Bottiglieri, Hidekazu Tsukamoto, Gary Kanel, Samuel W. French, José M. Mato, Rex Moats, Edward Grant

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment. Chronic liver disease often leads to impaired hepatic S-adenosylmethionine (SAMe) biosynthesis, and mice with SAMe deficiency develop HCC spontaneously. SAMe is antiapoptotic in normal hepatocytes but proapoptotic in cancerous hepatocytes. The present study investigated SAMe's effectiveness in prevention and treatment of HCC. Two weeks after injecting 2.5 million H4IIE cells into the liver parenchyma of ACI rats, they typically form a 1-cm tumor. When SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM (over 10-fold) 24 hours later. This regimen, started 1 day after injecting H4IIE cells and continued for 10 days, was able to reduce tumor establishment and growth. However, if intravenous SAMe was started after HCC had already developed, it was ineffective in reducing tumor growth for 24 days. Although plasma SAMe levels remained elevated, hepatic SAMe levels were minimally increased (30% higher). Chronic SAMe administration led to induction of hepatic methyltransferases, which prevented SAMe accumulation. To see if SAMe's preventive effect on tumor establishment involves angiogenesis, the effect of SAMe on angiogenesis genes was studied. SAMe treatment of H4IIE cells altered the expression of several genes with the net effect of inhibiting angiogenesis. These changes were confirmed at the protein level and functionally in human umbilical vein endothelial cells. Conclusion: SAMe is effective in preventing HCC establishment but ineffective in treating established HCC because of induction of hepatic methyltransferases, which prevents SAMe level to reach high enough to kill liver cancer cells. SAMe's chemopreventive effect may be related to its proapoptotic action and its ability to inhibit angiogenesis.

Original languageEnglish (US)
Pages (from-to)462-471
Number of pages10
JournalHepatology
Volume50
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

S-Adenosylmethionine
Chemoprevention
Hepatocellular Carcinoma
Therapeutics
Liver
Methyltransferases
Neoplasms
Hepatocytes
Inbred ACI Rats
Angiogenesis Inducing Agents
Human Umbilical Vein Endothelial Cells
Liver Neoplasms
Growth
Intravenous Infusions

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. / Lu, Shelly C.; Ramani, Komal; Ou, Xiaopeng; Lin, Mark T; Yu, Victor; Ko, Kwangsuk; Park, Ryan; Bottiglieri, Teodoro; Tsukamoto, Hidekazu; Kanel, Gary; French, Samuel W.; Mato, José M.; Moats, Rex; Grant, Edward.

In: Hepatology, Vol. 50, No. 2, 2009, p. 462-471.

Research output: Contribution to journalArticle

Lu, SC, Ramani, K, Ou, X, Lin, MT, Yu, V, Ko, K, Park, R, Bottiglieri, T, Tsukamoto, H, Kanel, G, French, SW, Mato, JM, Moats, R & Grant, E 2009, 'S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model', Hepatology, vol. 50, no. 2, pp. 462-471. https://doi.org/10.1002/hep.22990
Lu, Shelly C. ; Ramani, Komal ; Ou, Xiaopeng ; Lin, Mark T ; Yu, Victor ; Ko, Kwangsuk ; Park, Ryan ; Bottiglieri, Teodoro ; Tsukamoto, Hidekazu ; Kanel, Gary ; French, Samuel W. ; Mato, José M. ; Moats, Rex ; Grant, Edward. / S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. In: Hepatology. 2009 ; Vol. 50, No. 2. pp. 462-471.
@article{85393817ab0b480ebc2dc4d30a5c7404,
title = "S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model",
abstract = "Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment. Chronic liver disease often leads to impaired hepatic S-adenosylmethionine (SAMe) biosynthesis, and mice with SAMe deficiency develop HCC spontaneously. SAMe is antiapoptotic in normal hepatocytes but proapoptotic in cancerous hepatocytes. The present study investigated SAMe's effectiveness in prevention and treatment of HCC. Two weeks after injecting 2.5 million H4IIE cells into the liver parenchyma of ACI rats, they typically form a 1-cm tumor. When SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM (over 10-fold) 24 hours later. This regimen, started 1 day after injecting H4IIE cells and continued for 10 days, was able to reduce tumor establishment and growth. However, if intravenous SAMe was started after HCC had already developed, it was ineffective in reducing tumor growth for 24 days. Although plasma SAMe levels remained elevated, hepatic SAMe levels were minimally increased (30{\%} higher). Chronic SAMe administration led to induction of hepatic methyltransferases, which prevented SAMe accumulation. To see if SAMe's preventive effect on tumor establishment involves angiogenesis, the effect of SAMe on angiogenesis genes was studied. SAMe treatment of H4IIE cells altered the expression of several genes with the net effect of inhibiting angiogenesis. These changes were confirmed at the protein level and functionally in human umbilical vein endothelial cells. Conclusion: SAMe is effective in preventing HCC establishment but ineffective in treating established HCC because of induction of hepatic methyltransferases, which prevents SAMe level to reach high enough to kill liver cancer cells. SAMe's chemopreventive effect may be related to its proapoptotic action and its ability to inhibit angiogenesis.",
author = "Lu, {Shelly C.} and Komal Ramani and Xiaopeng Ou and Lin, {Mark T} and Victor Yu and Kwangsuk Ko and Ryan Park and Teodoro Bottiglieri and Hidekazu Tsukamoto and Gary Kanel and French, {Samuel W.} and Mato, {Jos{\'e} M.} and Rex Moats and Edward Grant",
year = "2009",
doi = "10.1002/hep.22990",
language = "English (US)",
volume = "50",
pages = "462--471",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model

AU - Lu, Shelly C.

AU - Ramani, Komal

AU - Ou, Xiaopeng

AU - Lin, Mark T

AU - Yu, Victor

AU - Ko, Kwangsuk

AU - Park, Ryan

AU - Bottiglieri, Teodoro

AU - Tsukamoto, Hidekazu

AU - Kanel, Gary

AU - French, Samuel W.

AU - Mato, José M.

AU - Moats, Rex

AU - Grant, Edward

PY - 2009

Y1 - 2009

N2 - Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment. Chronic liver disease often leads to impaired hepatic S-adenosylmethionine (SAMe) biosynthesis, and mice with SAMe deficiency develop HCC spontaneously. SAMe is antiapoptotic in normal hepatocytes but proapoptotic in cancerous hepatocytes. The present study investigated SAMe's effectiveness in prevention and treatment of HCC. Two weeks after injecting 2.5 million H4IIE cells into the liver parenchyma of ACI rats, they typically form a 1-cm tumor. When SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM (over 10-fold) 24 hours later. This regimen, started 1 day after injecting H4IIE cells and continued for 10 days, was able to reduce tumor establishment and growth. However, if intravenous SAMe was started after HCC had already developed, it was ineffective in reducing tumor growth for 24 days. Although plasma SAMe levels remained elevated, hepatic SAMe levels were minimally increased (30% higher). Chronic SAMe administration led to induction of hepatic methyltransferases, which prevented SAMe accumulation. To see if SAMe's preventive effect on tumor establishment involves angiogenesis, the effect of SAMe on angiogenesis genes was studied. SAMe treatment of H4IIE cells altered the expression of several genes with the net effect of inhibiting angiogenesis. These changes were confirmed at the protein level and functionally in human umbilical vein endothelial cells. Conclusion: SAMe is effective in preventing HCC establishment but ineffective in treating established HCC because of induction of hepatic methyltransferases, which prevents SAMe level to reach high enough to kill liver cancer cells. SAMe's chemopreventive effect may be related to its proapoptotic action and its ability to inhibit angiogenesis.

AB - Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment. Chronic liver disease often leads to impaired hepatic S-adenosylmethionine (SAMe) biosynthesis, and mice with SAMe deficiency develop HCC spontaneously. SAMe is antiapoptotic in normal hepatocytes but proapoptotic in cancerous hepatocytes. The present study investigated SAMe's effectiveness in prevention and treatment of HCC. Two weeks after injecting 2.5 million H4IIE cells into the liver parenchyma of ACI rats, they typically form a 1-cm tumor. When SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM (over 10-fold) 24 hours later. This regimen, started 1 day after injecting H4IIE cells and continued for 10 days, was able to reduce tumor establishment and growth. However, if intravenous SAMe was started after HCC had already developed, it was ineffective in reducing tumor growth for 24 days. Although plasma SAMe levels remained elevated, hepatic SAMe levels were minimally increased (30% higher). Chronic SAMe administration led to induction of hepatic methyltransferases, which prevented SAMe accumulation. To see if SAMe's preventive effect on tumor establishment involves angiogenesis, the effect of SAMe on angiogenesis genes was studied. SAMe treatment of H4IIE cells altered the expression of several genes with the net effect of inhibiting angiogenesis. These changes were confirmed at the protein level and functionally in human umbilical vein endothelial cells. Conclusion: SAMe is effective in preventing HCC establishment but ineffective in treating established HCC because of induction of hepatic methyltransferases, which prevents SAMe level to reach high enough to kill liver cancer cells. SAMe's chemopreventive effect may be related to its proapoptotic action and its ability to inhibit angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=68949180034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949180034&partnerID=8YFLogxK

U2 - 10.1002/hep.22990

DO - 10.1002/hep.22990

M3 - Article

C2 - 19444874

AN - SCOPUS:68949180034

VL - 50

SP - 462

EP - 471

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -